DK1601670T3 - Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf

Info

Publication number
DK1601670T3
DK1601670T3 DK04717398T DK04717398T DK1601670T3 DK 1601670 T3 DK1601670 T3 DK 1601670T3 DK 04717398 T DK04717398 T DK 04717398T DK 04717398 T DK04717398 T DK 04717398T DK 1601670 T3 DK1601670 T3 DK 1601670T3
Authority
DK
Denmark
Prior art keywords
azacycloalkane
arylvinyl
compounds
processes
preparation
Prior art date
Application number
DK04717398T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey Daniel Schmitt
Gary Maurice Dull
Arielle Genevois-Borella
Marc Capet
Michel Cheve
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK1601670T3 publication Critical patent/DK1601670T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04717398T 2003-03-05 2004-03-04 Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf DK1601670T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
PCT/US2004/006530 WO2004078752A1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
DK1601670T3 true DK1601670T3 (da) 2008-08-25

Family

ID=32926772

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04717398T DK1601670T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf
DK09075124.9T DK2085395T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-forbindelser og fremgangsmåder til fremstilling og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09075124.9T DK2085395T3 (da) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-forbindelser og fremgangsmåder til fremstilling og anvendelser deraf

Country Status (31)

Country Link
US (8) US7098331B2 (https=)
EP (3) EP1601670B1 (https=)
JP (3) JP4663627B2 (https=)
KR (4) KR101185541B1 (https=)
CN (3) CN100526308C (https=)
AR (3) AR043469A1 (https=)
AT (3) ATE496046T1 (https=)
AU (3) AU2004217903B2 (https=)
BR (1) BRPI0409576A (https=)
CA (1) CA2516514C (https=)
CL (1) CL2004000452A1 (https=)
CY (2) CY1110391T1 (https=)
DE (2) DE602004013553D1 (https=)
DK (2) DK1601670T3 (https=)
EA (3) EA010870B1 (https=)
ES (3) ES2385941T3 (https=)
GT (1) GT200400033A (https=)
IL (3) IL170155A (https=)
JO (1) JO2488B1 (https=)
MX (1) MXPA05009386A (https=)
NO (3) NO331920B1 (https=)
NZ (1) NZ541795A (https=)
PA (1) PA8597201A1 (https=)
PE (1) PE20040930A1 (https=)
PL (5) PL394600A1 (https=)
PT (2) PT1601670E (https=)
SI (2) SI1601670T1 (https=)
TW (3) TW200927746A (https=)
UY (1) UY28218A1 (https=)
WO (1) WO2004078752A1 (https=)
ZA (1) ZA200506790B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
PL3279195T3 (pl) * 2008-12-01 2020-12-14 Oyster Point Pharma, Inc. Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CN102802630A (zh) * 2009-06-17 2012-11-28 塔加西普特公司 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍
PH12012501068A1 (en) 2009-12-07 2013-02-04 Targacept Inc 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands
WO2011112428A2 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ATE491689T1 (de) 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
JP2003501416A (ja) 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
JP2003529547A (ja) 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
JP2003513054A (ja) 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
PL378415A1 (pl) 2006-04-03
IL170155A (en) 2013-08-29
IL197890A (en) 2013-11-28
AU2004217903A1 (en) 2004-09-16
SI1601670T1 (sl) 2008-10-31
TW200505909A (en) 2005-02-16
EA019240B1 (ru) 2014-02-28
CN101255155A (zh) 2008-09-03
ES2389106T3 (es) 2012-10-23
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
AU2008258187A1 (en) 2009-01-15
PL216979B1 (pl) 2014-06-30
NO20054120L (no) 2005-10-03
KR20120014236A (ko) 2012-02-16
JO2488B1 (en) 2009-10-05
PL2085395T3 (pl) 2011-05-31
AR043469A1 (es) 2005-07-27
EA010870B1 (ru) 2008-12-30
AU2008258188B2 (en) 2011-02-24
ATE394394T1 (de) 2008-05-15
EA200801764A1 (ru) 2008-12-30
PE20040930A1 (es) 2005-02-18
US8633222B2 (en) 2014-01-21
US7714001B2 (en) 2010-05-11
AU2004217903B2 (en) 2010-03-04
NO20091888L (no) 2005-10-03
BRPI0409576A (pt) 2006-04-18
AR070570A2 (es) 2010-04-21
CN101550132B (zh) 2012-03-28
PA8597201A1 (es) 2004-09-28
KR100953150B1 (ko) 2010-04-19
SI2085395T1 (sl) 2011-05-31
CN1756754A (zh) 2006-04-05
JP2009292825A (ja) 2009-12-17
KR20060006006A (ko) 2006-01-18
EP1947100B1 (en) 2011-07-27
MXPA05009386A (es) 2005-11-04
UY28218A1 (es) 2005-06-30
PL1601670T3 (pl) 2008-10-31
ATE517893T1 (de) 2011-08-15
PL215059B1 (pl) 2013-10-31
EP1601670A1 (en) 2005-12-07
EA014714B1 (ru) 2011-02-28
KR20090021227A (ko) 2009-02-27
US20080293778A1 (en) 2008-11-27
DK2085395T3 (da) 2011-04-18
EP1947100A1 (en) 2008-07-23
US20100267776A1 (en) 2010-10-21
CL2004000452A1 (es) 2005-05-20
JP4663627B2 (ja) 2011-04-06
KR20090021228A (ko) 2009-02-27
US8063068B2 (en) 2011-11-22
HK1116800A1 (en) 2009-01-02
JP2010001296A (ja) 2010-01-07
US20100010042A1 (en) 2010-01-14
EP2085395B1 (en) 2011-01-19
CA2516514C (en) 2012-02-07
TWI339662B (en) 2011-04-01
HK1084949A1 (en) 2006-08-11
CY1111615T1 (el) 2015-10-07
US8067443B2 (en) 2011-11-29
GT200400033A (es) 2005-05-29
US20040176348A1 (en) 2004-09-09
CN101550132A (zh) 2009-10-07
CA2516514A1 (en) 2004-09-16
US7098331B2 (en) 2006-08-29
EA200900706A1 (ru) 2009-10-30
EP1601670B1 (en) 2008-05-07
US20150164894A1 (en) 2015-06-18
PT2085395E (pt) 2011-04-20
EA200501425A1 (ru) 2006-02-24
TWI377204B (en) 2012-11-21
JP5537084B2 (ja) 2014-07-02
ES2309507T3 (es) 2008-12-16
CN100526308C (zh) 2009-08-12
KR101018083B1 (ko) 2011-03-02
ES2385941T3 (es) 2012-08-03
NO332293B1 (no) 2012-08-20
JP5537085B2 (ja) 2014-07-02
NO20092231L (no) 2005-10-03
WO2004078752A1 (en) 2004-09-16
NO331920B1 (no) 2012-04-30
US20060094732A1 (en) 2006-05-04
AU2008258188A1 (en) 2009-01-15
TW200927745A (en) 2009-07-01
PL394604A1 (pl) 2011-07-18
IL197889A (en) 2013-03-24
EP2085395A1 (en) 2009-08-05
TW200927746A (en) 2009-07-01
HK1130254A1 (en) 2009-12-24
ZA200506790B (en) 2006-05-31
AU2008258187B2 (en) 2010-08-05
JP2006519868A (ja) 2006-08-31
US20140107164A1 (en) 2014-04-17
KR101185541B1 (ko) 2012-09-24
NZ541795A (en) 2008-03-28
DE602004031165D1 (de) 2011-03-03
PL394600A1 (pl) 2011-07-18
ATE496046T1 (de) 2011-02-15
NO20054120D0 (no) 2005-09-05
DE602004013553D1 (de) 2008-06-19
US20110152293A1 (en) 2011-06-23
PT1601670E (pt) 2008-07-11

Similar Documents

Publication Publication Date Title
CY2023008I2 (el) Χημικες ενωσεις
IS2935B (is) Misnotkunarvarið lyfjaform til skömmtunar um húð
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1601670T3 (da) Arylvinylazacycloalkanforbindelser og fremgangsmåder til fremstilling og anvendelse deraf
IS8320A (is) N-staðgengnir pýrasólýl-amidýl-bensimidasólýl
DE602004031845D1 (de) Ng
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
DE602004009744D1 (de) Reagenzbehälter
ATE363895T1 (de) Zubereitungen enthaltend sucralose
ATE469878T1 (de) Aminobenzophenonverbindungen
NO20055459D0 (no) Prosesser
SK4326U (sk) Farmaceutická kompozícia s predĺženým uvoľňovaním
DE50204020D1 (de) Mikrotom
SE0302091L (sv) Genomföring
DE502004002225D1 (de) Selbstemulgierende Zubereitungen
EP1664117A4 (en) IMMUNOGENIC
DE602004014804D1 (de) Haltenden tabletten
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
DE602004018799D1 (de) Ng
DE60328306D1 (de) Drucktuch
DK1639107T3 (da) Forbedrede proteaser og fremgangsmåder til fremstilling deraf
ATE514681T1 (de) N-substituierte pyrazolylcarboxanilide
DE50200752D1 (de) Mikrotom